Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib Add-on in Steroid-refractory Graft-vs-host Disease After Allogeneic Stem Cell Transplantation: a Single Institutional Experience

NCT05663827 is registered in ClinicalTrials.gov with Yi-Lun Wang as lead sponsor.

NCT NCT05663827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05663827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib Add-on in Steroid-refractory Graft-vs-host Disease After Allogeneic Stem Cell Transplantation: a Single Institutional Experience
Lead sponsor
Yi-Lun Wang
Phase
Phase 3
Overall status
Completed
Start date
January 1, 2019
Completion date
November 30, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

steroid refractory gvhd